Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 01, 2008. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 6,015,075,749 Ordinary shares of 25p each.
- Treasury Shares: 504,194,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,510,881,591.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data or discussion of changes in share capital is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share counts intended for shareholder calculation purposes under Financial Services Authority rules.
Important Facts for Investors
- Investors should verify the total number of voting rights (5,510,881,591) as the denominator for determining notification requirements under Disclosure and Transparency Rules.
- Confirm the distinction between total issued shares and shares held in Treasury when calculating beneficial ownership.
- Note that this filing contains no financial performance data or strategic outlook.